CAPR stock Statistics — Capricor Therapeutics, INC. filings, insiders & smart money

COMMON STOCK · NASDAQ

Price and daily changeSign in

Earnings9 Nov 2026

52-week rangeSign inDay rangeSign in

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Beta: Sign in
Shares outstandingAs of 2026-08-13 · filed common shares: 58.13M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 0.42%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 38.16%
Short ratioDays to cover, as published by FINRA: 1.99
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 42.70%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 44.70%
Avg volume (10D)

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Gross margin: —
Operating margin (quarter)Quarter: 2024-07-01 to 2024-09-30 · Not annualized: -575.24%
Net margin: —
EBITDA margin (nine months)Nine months: 2024-01-01 to 2024-09-30 · Not annualized: -303.57%
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: -73.70%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -51.53%

Sign in

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, TTM to Jun 26

-2.45

EPS (fwd)

Cash & equivalentsas of Jun 26: $20.93M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $91.04M
Debt / equityas of Jun 26: 36.98%
Current ratioas of Jun 26: 7.35
Quick ratio: —
Operating cash flowTTM to Jun 26: -$103.99M
Free cash flowUnadjusted FCF = CFO − capex · TTM to Jun 26: -$114.90M
TTM revenue / diluted share: —